A new analysis from MedCity News pushes back on the conventional wisdom that medtech venture capital is fading. The author, prompted by repeated assertions of decline, dug into the data expecting to find shrinking investor interest, inflated valuations, and a weak exit environment. Instead, the evidence suggested a more complicated reality.
The piece does not offer a simple rebuttal, but it does argue that the real story is more nuanced than the thesis of decline. While the author does not spell out specific figures in the excerpt, the central takeaway is that broad claims about medtech VC may be missing important context.
Because this is a single source, there is no competing view to compare. The article itself frames the gap between perception and data, and it positions the data as the more reliable guide to what is actually happening in medtech investing.